[ad_1]
Reuters – June 10, 2022
LONDON, June 10 (Reuters) – GSK (GSK.L) goals to get its respiratory syncytial virus (RSV) vaccine to regulators for evaluate later this 12 months, after interim information confirmed the vaccine was efficient in a keenly-watched late-stage research involving older adults.
RSV is a number one reason behind pneumonia in toddlers and the aged, however the advanced molecular construction of the virus and security considerations have stymied efforts to develop a vaccine because the virus was first found in 1956.
Firms together with Pfizer (PFE.N), J&J (JNJ.N), Sanofi (SASY.PA), Moderna (MRNA.O) and AstraZeneca (AZN.L), are additionally racing to get an RSV remedy or vaccine accepted.
The newest GSK trial is the primary to point out statistically important efficacy for RSV in adults aged 60 years and older, the British drugmaker mentioned of the continuing research on Friday.
The corporate’s shares had been up about 2.4% in early commerce.
If accepted, the RSV vaccine is anticipated to generate billions for GSK, which is already the world’s greatest vaccine maker by gross sales however has confronted strain from activist traders resembling Elliott Managementwho have urged the London-based firm to shore up its drug pipeline.
Learn Extra
[ad_2]
Source link
